Holen Sie sich die Stockscreener-App
387.85
1.73%
-6.84
Handel nachbörslich:
387.14
-0.71
-0.18%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ELV?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$394.69
Offen:
$388.91
24-Stunden-Volumen:
1.51M
Relative Volume:
0.80
Marktkapitalisierung:
$84.23B
Einnahmen:
$200.42B
Nettoeinkommen (Verlust:
$5.24B
KGV:
16.50
EPS:
23.5042
Netto-Cashflow:
$6.45B
1W Leistung:
-3.58%
1M Leistung:
+12.50%
6M Leistung:
+14.57%
1J Leistung:
+4.19%
1-Tages-Spanne:
$384.30
$392.69
1-Wochen-Bereich:
$384.30
$408.00
52-Wochen-Spanne:
$273.71
$408.00
Elevance Health Inc Stock (ELV) Company Profile
Firmenname
Elevance Health Inc
Sektor
Branche
Telefon
(800) 331-1476
Adresse
220 VIRGINIA AVENUE, INDIANAPOLIS
Compare ELV vs UNH, CVS, CI, HUM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ELV
Elevance Health Inc
|
387.85 | 85.71B | 200.42B | 5.24B | 6.45B | 23.50 |
UNH
Unitedhealth Group Inc
|
376.86 | 352.79B | 449.71B | 12.81B | 19.67B | 13.24 |
CVS
Cvs Health Corp
|
90.73 | 118.99B | 407.94B | 2.90B | 7.39B | 2.2771 |
CI
Cigna Group
|
280.83 | 75.72B | 278.13B | 6.74B | 7.66B | 23.60 |
HUM
Humana Inc
|
301.69 | 36.97B | 137.20B | 1.15B | 1.27B | 9.3439 |
Elevance Health Inc Stock (ELV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-08 | Eingeleitet | Evercore ISI | In-line |
| 2026-02-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-01-08 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-12-19 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2025-10-14 | Eingeleitet | Goldman | Neutral |
| 2025-07-21 | Herabstufung | Argus | Buy → Hold |
| 2025-07-18 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-04-15 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2025-03-17 | Hochstufung | Argus | Hold → Buy |
| 2025-01-22 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2024-10-18 | Herabstufung | Argus | Buy → Hold |
| 2024-07-18 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-06-24 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-05-30 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-03-06 | Eingeleitet | Barclays | Overweight |
| 2023-07-12 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-04-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-04-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-03-28 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-09-09 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-08-22 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
Alle ansehen
Elevance Health Inc Aktie (ELV) Neueste Nachrichten
Elevance Health Stock Analysis: Guidance Raised to $27, Street High at $498, TIKR Target at $534 - TIKR.com
Barclays Adjusts Elevance Health Price Target to $480 From $408, Maintains Overweight Rating - marketscreener.com
Elevance Health, Inc. (ELV) Stock Analysis: Exploring a Promising 1.5% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
What Elevance Health (ELV)'s Raised EPS Outlook and Insider Stock Sale Means For Shareholders - Yahoo Finance
Elevance Health Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Elevance Health Price Target Raised to $460.00/Share From $400.00 by UBS - Moomoo
Elevance Health (ELV) Up 12.6% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Are Wall Street Analysts Predicting Elevance Stock Will Climb or Sink? - Barchart.com
UBS Adjusts Price Target on Elevance Health to $460 From $400, Maintains Buy Rating - marketscreener.com
Top Elevance Health (ELV) Competitors 2026 - MarketBeat
Elevance Health Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Elevance executive ordered to testify in Medicare Advantage fraud case - statnews.com
Analysts’ Top Healthcare Picks: Protara Therapeutics (TARA), Elevance Health (ELV) - The Globe and Mail
Defensive Market Strategies Fund's Elevance Health Inc(ELV) Holding History - GuruFocus
Elevance Health CAO Ronald Penczek sells $617,192 of company stock - Investing.com
Elevance Health Inc. stock outperforms competitors despite losses on the day - MarketWatch
Elevance Health Insider Sold Shares Worth $617,192, According to a Recent SEC Filing - marketscreener.com
Elevance Health (NYSE: ELV) CAO exercises options, sells 1,531 shares - Stock Titan
Elevance Health Is Maintained at Outperform by Mizuho - Moomoo
Deutsche Bank Upgrades Elevance Health to Buy From Hold, Adjusts PT to $498 From $363 - marketscreener.com
Mizuho Adjusts Price Target on Elevance Health to $435 From $385, Maintains Outperform Rating - marketscreener.com
ELV (NYSE: ELV) Form 144 filed for 1,531 shares on 05/19/2026 - Stock Titan
How providers are responding to Elevance’s out-of-network policy - Modern Healthcare
Elevance Health, Inc. (ELV) Stock Analysis: Navigating a Stable Healthcare Giant with Strategic Growth Potential - DirectorsTalk Interviews
Elevance Health Advances Efforts to Close Critical Gaps in Mental Health Care - Business Wire
Bessemer Group Inc. Sells 4,178 Shares of Elevance Health, Inc. $ELV - MarketBeat
Gail Boudreaux - Britannica
Greene County hospital serves Anthem with second breach notice over claim payments - Inside INdiana Business
Director at Elevance Health (ELV) receives 563 deferred stock units as board compensation - Stock Titan
Elevance Health (ELV) director Amy Schulman receives 563 deferred stock units - Stock Titan
Elevance Health (ELV) director receives 563 deferred stock units as board compensation - Stock Titan
Elevance Health (ELV) director Ramiro Peru receives 563 deferred stock units as board pay - Stock Titan
Board member gets 563 deferred stock units at Elevance Health (NYSE: ELV) - Stock Titan
Elevance Health (ELV) director Bahija Jallal awarded 563 deferred stock units - Stock Titan
Board member at Elevance Health (NYSE: ELV) receives 563 deferred stock units - Stock Titan
Elevance Health (ELV) director receives 563 deferred stock units as compensation - Stock Titan
Elevance Health (ELV) director receives 563 deferred stock units as compensation award - Stock Titan
Director at Elevance Health (NYSE: ELV) receives 563 deferred units - Stock Titan
Why UnitedHealthcare and other insurers are padding reserves - Modern Healthcare News
Elevance Health Inc (ELV) Stock Price, Trades & News - GuruFocus
Elevance Health (ELV) Announces Results of Annual Shareholder Me - GuruFocus
RIK SAYLOR FINANCIAL, INC.'s Elevance Health Inc(ELV) Holding History - GuruFocus
Elevance Health shareholders elect directors and approve executive pay at annual meeting - Investing.com
Elevance Health Shareholders Back Directors, Pay and Auditor - TipRanks
Elevance Health (ELV) 2026 annual meeting: directors elected, pay and auditor backed - Stock Titan
Elevance Health stock (US2855211023): Health insurance giant reports strong Q1 amid sector shifts - AD HOC NEWS
What Does Elevance Health's Q1 2026 Performance Signal for Investors - Kavout
Elevance Health Inc (BSP:E1LV34) Stock Price & 30 Year Financial Data - GuruFocus
A Look at Elevance Health Inc (ELV) After 4.0% Gain -- GF Value $518.29 vs Price $393.30 - GuruFocus
Elevance Health Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Will UnitedHealth's New Optum Rx Model Boost PBM Pricing Transparency? - TradingView
Finanzdaten der Elevance Health Inc-Aktie (ELV)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.89%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):